University of Washington

University of South Florida

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Priyesh Jain

Shaoyi Jiang

Harihara Subramanian Sundaram

Andrew William Sinclair

Jean-René Ella-Menye

Tao Bai

Mark L McLaughlin

William S Dalton

Lori Hazlehurst

Bowen Li

Hsiang-Chieh Hung

Yang Li

Peng Zhang

Jinrong Ma

Jean René Ella-Menye

Mark Mclaughlin

Mary Elizabeth O'Kelly

Zwitterionic phosphatidylserine (ZPS) monomers, ZPS polymers and ZPS copolymers, methods for making the ZPS monomers, ZPS polymers, and ZPS copolymers, compositions and materials that include ZPS polymers and ZPS copolymers, and methods for using the ZPS monomers, ZPS polymers, and ZPS copolymers.

Immunosuppressive materials and related methods

N-oxide and monomers, N-oxide polymers and copolymers, methods for making the N-oxide monomers, polymers, and copolymers, compositions and materials that include N-oxide polymers and copolymers, and methods for using the N-oxide monomers, N-oxide polymers, and N-oxide copolymers.

N-oxide and ectoine monomers, polymers, their compositions, and related methods

Free-standing non-fouling polymers and polymeric compositions, monomers and macromonomers for making the polymers and polymeric compositions, objects made from the polymers and polymeric compositions, and methods for making and using the polymers and polymeric compositions.

Free-standing non-fouling polymers, their compositions, and related monomers

Functionalized zwitterionic and mixed charge polymers and copolymers, methods for making the polymers and copolymers, hydrogels prepared from the functionalized zwitterionic and mixed charge polymers and copolymers, methods for making and using the hydrogels, and zwitterionic and mixed charge polymers and copolymers for administration for therapeutic agents.

Functionalized zwitterionic and mixed charge polymers, related hydrogels, and methods for their use

Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

Integrin interaction inhibitors for the treatment of cancer

Growing community of inventors

Seattle, WA, United States of America

Priyesh Jain